Dayvigo

Overview

lemborexant

orexin antagonist

• CYP3A4 substrate
• CYP2B6 inducer, weak
• CNS depression

Avoid/Use Alternative

• apalutamide
Dayvigo (lemborexant)

+

apalutamide

1 interaction

Avoid/Use Alternative

lemborexant + apalutamide

avoid combo: combo may decr. lemborexant levels, efficacy (hepatic metabolism induced)

• atazanavir
Dayvigo (lemborexant)

+

atazanavir

1 interaction

Avoid/Use Alternative

lemborexant + atazanavir

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• avacopan
Dayvigo (lemborexant)

+

avacopan

3 interactions

Avoid/Use Alternative

lemborexant + avacopan

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• bosentan
Dayvigo (lemborexant)

+

bosentan

2 interactions

Avoid/Use Alternative

lemborexant + bosentan

avoid combo: combo may decr. lemborexant levels, efficacy (hepatic metabolism induced)

• carbamazepine
Dayvigo (lemborexant)

+

carbamazepine

1 interaction

Avoid/Use Alternative

lemborexant + carbamazepine

avoid combo: combo may decr. lemborexant levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• ceritinib
Dayvigo (lemborexant)

+

ceritinib

1 interaction

Avoid/Use Alternative

lemborexant + ceritinib

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• chloramphenicol
Dayvigo (lemborexant)

+

chloramphenicol

3 interactions

Avoid/Use Alternative

lemborexant + chloramphenicol

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• ciprofloxacin
Dayvigo (lemborexant)

+

ciprofloxacin

1 interaction

Avoid/Use Alternative

lemborexant + ciprofloxacin

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• clarithromycin
Dayvigo (lemborexant)

+

clarithromycin

2 interactions

Avoid/Use Alternative

lemborexant + clarithromycin

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• clonidine
Dayvigo (lemborexant)

+

clonidine

2 interactions

Avoid/Use Alternative

lemborexant + clonidine

if ADHD use, avoid combo; otherwise, consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• codeine
Dayvigo (lemborexant)

+

codeine

2 interactions

Avoid/Use Alternative

lemborexant + codeine

avoid combo if antitussive use; otherwise monitor respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• crizotinib
Dayvigo (lemborexant)

+

crizotinib

2 interactions

Avoid/Use Alternative

lemborexant + crizotinib

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• dabrafenib
Dayvigo (lemborexant)

+

dabrafenib

1 interaction

Avoid/Use Alternative

lemborexant + dabrafenib

avoid combo: combo may decr. lemborexant levels, efficacy (hepatic metabolism induced)

• danazol
Dayvigo (lemborexant)

+

danazol

3 interactions

Avoid/Use Alternative

lemborexant + danazol

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• daridorexant
Dayvigo (lemborexant)

+

daridorexant

1 interaction

Avoid/Use Alternative

lemborexant + daridorexant

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects, duplicate therapy)

• darunavir
Dayvigo (lemborexant)

+

darunavir

2 interactions

Avoid/Use Alternative

lemborexant + darunavir

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• doxylamine
Dayvigo (lemborexant)

+

doxylamine

1 interaction

Avoid/Use Alternative

lemborexant + doxylamine

avoid combo if doxylamine use for pregnancy-related nausea/vomiting, otherwise consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• duvelisib
Dayvigo (lemborexant)

+

duvelisib

1 interaction

Avoid/Use Alternative

lemborexant + duvelisib

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• efavirenz
Dayvigo (lemborexant)

+

efavirenz

3 interactions

Avoid/Use Alternative

lemborexant + efavirenz

avoid combo: combo may decr. lemborexant levels, efficacy; may decr. efavirenz levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• enzalutamide
Dayvigo (lemborexant)

+

enzalutamide

2 interactions

Avoid/Use Alternative

lemborexant + enzalutamide

avoid combo: combo may decr. lemborexant levels, efficacy (hepatic metabolism induced)

• estazolam
Dayvigo (lemborexant)

+

estazolam

1 interaction

Avoid/Use Alternative

lemborexant + estazolam

avoid combo: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• ethanol
Dayvigo (lemborexant)

+

ethanol

1 interaction

Avoid/Use Alternative

lemborexant + ethanol

ORAL ETHANOL: avoid combo; IV ETHANOL: use alternative or monitor respiratory rate; consider decreasing dose of one or both drugs: combo with oral ethanol or IV ethanol may increase lemborexant levels, risk of profound CNS and respiratory depression, psychomotor impairment, other adverse effects (additive effects, mechanism unknown)

• ethanol (in some formulations)
Dayvigo (lemborexant)

+

ethanol (in some formulations)

3 interactions

Avoid/Use Alternative

lemborexant + ethanol (in some formulations)

avoid combo: combo may incr. lemborexant levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (additive effects, mechanism unknown)

• etravirine
Dayvigo (lemborexant)

+

etravirine

1 interaction

Avoid/Use Alternative

lemborexant + etravirine

avoid combo: combo may decr. lemborexant levels, efficacy (hepatic metabolism induced)

• fedratinib
Dayvigo (lemborexant)

+

fedratinib

2 interactions

Avoid/Use Alternative

lemborexant + fedratinib

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• fluconazole
Dayvigo (lemborexant)

+

fluconazole

3 interactions

Avoid/Use Alternative

lemborexant + fluconazole

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• flurazepam
Dayvigo (lemborexant)

+

flurazepam

1 interaction

Avoid/Use Alternative

lemborexant + flurazepam

avoid combo: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• fosamprenavir
Dayvigo (lemborexant)

+

fosamprenavir

2 interactions

Avoid/Use Alternative

lemborexant + fosamprenavir

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• grapefruit
Dayvigo (lemborexant)

+

grapefruit

2 interactions

Avoid/Use Alternative

lemborexant + grapefruit

avoid grapefruit juice: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (GI metabolism inhibited)

• haloperidol
Dayvigo (lemborexant)

+

haloperidol

2 interactions

Avoid/Use Alternative

lemborexant + haloperidol

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• hydrocodone
Dayvigo (lemborexant)

+

hydrocodone

1 interaction

Avoid/Use Alternative

lemborexant + hydrocodone

avoid combo if antitussive use; otherwise monitor respiratory rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• idelalisib
Dayvigo (lemborexant)

+

idelalisib

2 interactions

Avoid/Use Alternative

lemborexant + idelalisib

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• isavuconazonium
Dayvigo (lemborexant)

+

isavuconazonium

2 interactions

Avoid/Use Alternative

lemborexant + isavuconazonium

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• itraconazole
Dayvigo (lemborexant)

+

itraconazole

1 interaction

Avoid/Use Alternative

lemborexant + itraconazole

avoid combo during and x2wk after itraconazole tx: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• kava
Dayvigo (lemborexant)

+

kava

1 interaction

Avoid/Use Alternative

lemborexant + kava

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ketoconazole
Dayvigo (lemborexant)

+

ketoconazole

2 interactions

Avoid/Use Alternative

lemborexant + ketoconazole

avoid combo during and up to 1wk after ketoconazole tx: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• lefamulin
Dayvigo (lemborexant)

+

lefamulin

2 interactions

Avoid/Use Alternative

lemborexant + lefamulin

ORAL LEFAMULIN: avoid combo; IV lefamulin use OK: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• letermovir
Dayvigo (lemborexant)

+

letermovir

2 interactions

Avoid/Use Alternative

lemborexant + letermovir

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• lonafarnib
Dayvigo (lemborexant)

+

lonafarnib

2 interactions

Avoid/Use Alternative

lemborexant + lonafarnib

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• lorlatinib
Dayvigo (lemborexant)

+

lorlatinib

1 interaction

Avoid/Use Alternative

lemborexant + lorlatinib

avoid combo: combo may decr. lemborexant levels, efficacy (hepatic metabolism induced)

• mavacamten
Dayvigo (lemborexant)

+

mavacamten

1 interaction

Avoid/Use Alternative

lemborexant + mavacamten

avoid combo: combo may decr. lemborexant levels, efficacy (hepatic metabolism induced)

• metoclopramide
Dayvigo (lemborexant)

+

metoclopramide

1 interaction

Avoid/Use Alternative

lemborexant + metoclopramide

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• midazolam
Dayvigo (lemborexant)

+

midazolam

2 interactions

Avoid/Use Alternative

lemborexant + midazolam

use alternative or monitor respiratory rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• mitapivat
Dayvigo (lemborexant)

+

mitapivat

2 interactions

Avoid/Use Alternative

lemborexant + mitapivat

avoid combo: combo may decr. lemborexant levels, efficacy (hepatic metabolism induced)

• modafinil
Dayvigo (lemborexant)

+

modafinil

1 interaction

Avoid/Use Alternative

lemborexant + modafinil

avoid combo: combo may decr. lemborexant levels, efficacy (hepatic metabolism induced)

• nafcillin
Dayvigo (lemborexant)

+

nafcillin

3 interactions

Avoid/Use Alternative

lemborexant + nafcillin

avoid combo: combo may decr. lemborexant levels, efficacy (hepatic metabolism induced)

• nefazodone
Dayvigo (lemborexant)

+

nefazodone

1 interaction

Avoid/Use Alternative

lemborexant + nefazodone

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited; additive effects)

• nelfinavir
Dayvigo (lemborexant)

+

nelfinavir

2 interactions

Avoid/Use Alternative

lemborexant + nelfinavir

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• nilotinib
Dayvigo (lemborexant)

+

nilotinib

2 interactions

Avoid/Use Alternative

lemborexant + nilotinib

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• norgestimate (contraceptive)
Dayvigo (lemborexant)

+

norgestimate (contraceptive)

1 interaction

Avoid/Use Alternative

lemborexant + norgestimate (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after lemborexant tx: combo may decr. norgestimate and active metabolites levels, contraceptive efficacy (hepatic metabolism induced)

• oxybate
Dayvigo (lemborexant)

+

oxybate

3 interactions

Avoid/Use Alternative

lemborexant + oxybate

use alternative or monitor respiratory rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, hypotension, syncope (additive effects)

• pacritinib
Dayvigo (lemborexant)

+

pacritinib

1 interaction

Avoid/Use Alternative

lemborexant + pacritinib

avoid combo: combo may decr. lemborexant levels, efficacy (hepatic metabolism induced)

• pentobarbital
Dayvigo (lemborexant)

+

pentobarbital

2 interactions

Avoid/Use Alternative

lemborexant + pentobarbital

avoid combo: combo may decr. lemborexant levels, efficacy; may incr. risk of CNS and respiratory depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• phenelzine
Dayvigo (lemborexant)

+

phenelzine

2 interactions

Avoid/Use Alternative

lemborexant + phenelzine

use alternative: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• phenytoin
Dayvigo (lemborexant)

+

phenytoin

2 interactions

Avoid/Use Alternative

lemborexant + phenytoin

avoid combo: combo may decr. lemborexant levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• primidone
Dayvigo (lemborexant)

+

primidone

2 interactions

Avoid/Use Alternative

lemborexant + primidone

avoid combo: combo may decr. lemborexant levels, efficacy; may incr. risk of CNS and respiratory depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• quazepam
Dayvigo (lemborexant)

+

quazepam

2 interactions

Avoid/Use Alternative

lemborexant + quazepam

avoid combo: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• repotrectinib
Dayvigo (lemborexant)

+

repotrectinib

2 interactions

Avoid/Use Alternative

lemborexant + repotrectinib

avoid combo: combo may decr. lemborexant levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• rifabutin
Dayvigo (lemborexant)

+

rifabutin

2 interactions

Avoid/Use Alternative

lemborexant + rifabutin

avoid combo: combo may decr. lemborexant levels, efficacy (hepatic metabolism induced)

• rifapentine
Dayvigo (lemborexant)

+

rifapentine

1 interaction

Avoid/Use Alternative

lemborexant + rifapentine

avoid combo: combo may decr. lemborexant levels, efficacy (hepatic metabolism induced)

• rilzabrutinib
Dayvigo (lemborexant)

+

rilzabrutinib

3 interactions

Avoid/Use Alternative

lemborexant + rilzabrutinib

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• ritonavir
Dayvigo (lemborexant)

+

ritonavir

1 interaction

Avoid/Use Alternative

lemborexant + ritonavir

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• ropeginterferon alfa-2b
Dayvigo (lemborexant)

+

ropeginterferon alfa-2b

2 interactions

Avoid/Use Alternative

lemborexant + ropeginterferon alfa-2b

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• sevabertinib
Dayvigo (lemborexant)

+

sevabertinib

2 interactions

Avoid/Use Alternative

lemborexant + sevabertinib

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• St. John's wort
Dayvigo (lemborexant)

+

St. John's wort

2 interactions

Avoid/Use Alternative

lemborexant + St. John's wort

avoid combo: combo may decr. lemborexant levels, efficacy (hepatic metabolism induced)

• temazepam
Dayvigo (lemborexant)

+

temazepam

2 interactions

Avoid/Use Alternative

lemborexant + temazepam

avoid combo: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• tipranavir
Dayvigo (lemborexant)

+

tipranavir

1 interaction

Avoid/Use Alternative

lemborexant + tipranavir

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• tranylcypromine
Dayvigo (lemborexant)

+

tranylcypromine

1 interaction

Avoid/Use Alternative

lemborexant + tranylcypromine

use alternative: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• trimethobenzamide
Dayvigo (lemborexant)

+

trimethobenzamide

1 interaction

Avoid/Use Alternative

lemborexant + trimethobenzamide

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tucatinib
Dayvigo (lemborexant)

+

tucatinib

3 interactions

Avoid/Use Alternative

lemborexant + tucatinib

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• verapamil
Dayvigo (lemborexant)

+

verapamil

1 interaction

Avoid/Use Alternative

lemborexant + verapamil

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• voriconazole
Dayvigo (lemborexant)

+

voriconazole

3 interactions

Avoid/Use Alternative

lemborexant + voriconazole

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• zaleplon
Dayvigo (lemborexant)

+

zaleplon

1 interaction

Avoid/Use Alternative

lemborexant + zaleplon

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• zolpidem
Dayvigo (lemborexant)

+

zolpidem

3 interactions

Avoid/Use Alternative

lemborexant + zolpidem

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• zuranolone
Dayvigo (lemborexant)

+

zuranolone

1 interaction

Avoid/Use Alternative

lemborexant + zuranolone

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

Monitor/Modify Tx

• 5-HTP
Dayvigo (lemborexant)

+

5-HTP

1 interaction

Monitor/Modify Tx

lemborexant + 5-HTP

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• aldesleukin
Dayvigo (lemborexant)

+

aldesleukin

2 interactions

Monitor/Modify Tx

lemborexant + aldesleukin

consider decr. dose of one or both drugs; withhold aldesleukin if mod-severe somnolence occurs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• alfentanil
Dayvigo (lemborexant)

+

alfentanil

1 interaction

Monitor/Modify Tx

lemborexant + alfentanil

monitor BP, respiratory rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, hypotension (additive effects)

• allopurinol
Dayvigo (lemborexant)

+

allopurinol

1 interaction

Monitor/Modify Tx

lemborexant + allopurinol

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• almotriptan
Dayvigo (lemborexant)

+

almotriptan

3 interactions

Monitor/Modify Tx

lemborexant + almotriptan

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• alprazolam
Dayvigo (lemborexant)

+

alprazolam

1 interaction

Monitor/Modify Tx

lemborexant + alprazolam

monitor respiratory rate; adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• amantadine
Dayvigo (lemborexant)

+

amantadine

2 interactions

Monitor/Modify Tx

lemborexant + amantadine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• amiodarone
Dayvigo (lemborexant)

+

amiodarone

1 interaction

Monitor/Modify Tx

lemborexant + amiodarone

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• amitriptyline
Dayvigo (lemborexant)

+

amitriptyline

2 interactions

Monitor/Modify Tx

lemborexant + amitriptyline

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• amlodipine
Dayvigo (lemborexant)

+

amlodipine

1 interaction

Monitor/Modify Tx

lemborexant + amlodipine

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• amoxapine
Dayvigo (lemborexant)

+

amoxapine

1 interaction

Monitor/Modify Tx

lemborexant + amoxapine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• apraclonidine ophthalmic
Dayvigo (lemborexant)

+

apraclonidine ophthalmic

1 interaction

Monitor/Modify Tx

lemborexant + apraclonidine ophthalmic

consider decr. dose of one or both drugs if apraclonidine IOP adjunct use; postop use OK: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• aripiprazole bimonthly injection
Dayvigo (lemborexant)

+

aripiprazole bimonthly injection

3 interactions

Monitor/Modify Tx

lemborexant + aripiprazole bimonthly injection

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• aripiprazole lauroxil
Dayvigo (lemborexant)

+

aripiprazole lauroxil

1 interaction

Monitor/Modify Tx

lemborexant + aripiprazole lauroxil

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• aripiprazole monthly injection
Dayvigo (lemborexant)

+

aripiprazole monthly injection

2 interactions

Monitor/Modify Tx

lemborexant + aripiprazole monthly injection

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• aripiprazole oral
Dayvigo (lemborexant)

+

aripiprazole oral

1 interaction

Monitor/Modify Tx

lemborexant + aripiprazole oral

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• asciminib
Dayvigo (lemborexant)

+

asciminib

2 interactions

Monitor/Modify Tx

lemborexant + asciminib

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• asenapine
Dayvigo (lemborexant)

+

asenapine

1 interaction

Monitor/Modify Tx

lemborexant + asenapine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• atorvastatin
Dayvigo (lemborexant)

+

atorvastatin

2 interactions

Monitor/Modify Tx

lemborexant + atorvastatin

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• baclofen
Dayvigo (lemborexant)

+

baclofen

1 interaction

Monitor/Modify Tx

lemborexant + baclofen

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• baclofen intrathecal
Dayvigo (lemborexant)

+

baclofen intrathecal

1 interaction

Monitor/Modify Tx

lemborexant + baclofen intrathecal

consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• belumosudil
Dayvigo (lemborexant)

+

belumosudil

1 interaction

Monitor/Modify Tx

lemborexant + belumosudil

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• berberine
Dayvigo (lemborexant)

+

berberine

1 interaction

Monitor/Modify Tx

lemborexant + berberine

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• bicalutamide
Dayvigo (lemborexant)

+

bicalutamide

2 interactions

Monitor/Modify Tx

lemborexant + bicalutamide

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• brexpiprazole
Dayvigo (lemborexant)

+

brexpiprazole

1 interaction

Monitor/Modify Tx

lemborexant + brexpiprazole

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• brimonidine topical
Dayvigo (lemborexant)

+

brimonidine topical

2 interactions

Monitor/Modify Tx

lemborexant + brimonidine topical

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• brivaracetam
Dayvigo (lemborexant)

+

brivaracetam

1 interaction

Monitor/Modify Tx

lemborexant + brivaracetam

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• bromocriptine
Dayvigo (lemborexant)

+

bromocriptine

2 interactions

Monitor/Modify Tx

lemborexant + bromocriptine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• brompheniramine
Dayvigo (lemborexant)

+

brompheniramine

1 interaction

Monitor/Modify Tx

lemborexant + brompheniramine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• buprenorphine
Dayvigo (lemborexant)

+

buprenorphine

1 interaction

Monitor/Modify Tx

lemborexant + buprenorphine

monitor respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• buspirone
Dayvigo (lemborexant)

+

buspirone

3 interactions

Monitor/Modify Tx

lemborexant + buspirone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• butorphanol
Dayvigo (lemborexant)

+

butorphanol

1 interaction

Monitor/Modify Tx

lemborexant + butorphanol

monitor respiratory rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• cannabidiol
Dayvigo (lemborexant)

+

cannabidiol

2 interactions

Monitor/Modify Tx

lemborexant + cannabidiol

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• cannabis
Dayvigo (lemborexant)

+

cannabis

1 interaction

Monitor/Modify Tx

lemborexant + cannabis

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• capivasertib
Dayvigo (lemborexant)

+

capivasertib

2 interactions

Monitor/Modify Tx

lemborexant + capivasertib

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• carbinoxamine
Dayvigo (lemborexant)

+

carbinoxamine

1 interaction

Monitor/Modify Tx

lemborexant + carbinoxamine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• cariprazine
Dayvigo (lemborexant)

+

cariprazine

1 interaction

Monitor/Modify Tx

lemborexant + cariprazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• carisoprodol
Dayvigo (lemborexant)

+

carisoprodol

3 interactions

Monitor/Modify Tx

lemborexant + carisoprodol

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• cetirizine
Dayvigo (lemborexant)

+

cetirizine

1 interaction

Monitor/Modify Tx

lemborexant + cetirizine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• chamomile, German
Dayvigo (lemborexant)

+

chamomile, German

2 interactions

Monitor/Modify Tx

lemborexant + chamomile, German

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• chlophedianol
Dayvigo (lemborexant)

+

chlophedianol

1 interaction

Monitor/Modify Tx

lemborexant + chlophedianol

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• chlorcyclizine
Dayvigo (lemborexant)

+

chlorcyclizine

2 interactions

Monitor/Modify Tx

lemborexant + chlorcyclizine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• chlordiazepoxide
Dayvigo (lemborexant)

+

chlordiazepoxide

1 interaction

Monitor/Modify Tx

lemborexant + chlordiazepoxide

consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• chlorpheniramine
Dayvigo (lemborexant)

+

chlorpheniramine

1 interaction

Monitor/Modify Tx

lemborexant + chlorpheniramine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• chlorpromazine
Dayvigo (lemborexant)

+

chlorpromazine

3 interactions

Monitor/Modify Tx

lemborexant + chlorpromazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• chlorzoxazone
Dayvigo (lemborexant)

+

chlorzoxazone

1 interaction

Monitor/Modify Tx

lemborexant + chlorzoxazone

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited; additive effects)

• cilostazol
Dayvigo (lemborexant)

+

cilostazol

2 interactions

Monitor/Modify Tx

lemborexant + cilostazol

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• cimetidine
Dayvigo (lemborexant)

+

cimetidine

1 interaction

Monitor/Modify Tx

lemborexant + cimetidine

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• citalopram
Dayvigo (lemborexant)

+

citalopram

2 interactions

Monitor/Modify Tx

lemborexant + citalopram

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• clemastine
Dayvigo (lemborexant)

+

clemastine

1 interaction

Monitor/Modify Tx

lemborexant + clemastine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• clobazam
Dayvigo (lemborexant)

+

clobazam

2 interactions

Monitor/Modify Tx

lemborexant + clobazam

monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• clomipramine
Dayvigo (lemborexant)

+

clomipramine

1 interaction

Monitor/Modify Tx

lemborexant + clomipramine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• clonazepam
Dayvigo (lemborexant)

+

clonazepam

1 interaction

Monitor/Modify Tx

lemborexant + clonazepam

monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• clorazepate
Dayvigo (lemborexant)

+

clorazepate

1 interaction

Monitor/Modify Tx

lemborexant + clorazepate

monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• clotrimazole oropharyngeal
Dayvigo (lemborexant)

+

clotrimazole oropharyngeal

1 interaction

Monitor/Modify Tx

lemborexant + clotrimazole oropharyngeal

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• clozapine
Dayvigo (lemborexant)

+

clozapine

2 interactions

Monitor/Modify Tx

lemborexant + clozapine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• cranberry
Dayvigo (lemborexant)

+

cranberry

1 interaction

Monitor/Modify Tx

lemborexant + cranberry

adjust max lemborexant dose to 5 mg/day, especially w/ large amounts of cranberry: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (GI metabolism inhibited)

• cyclobenzaprine
Dayvigo (lemborexant)

+

cyclobenzaprine

2 interactions

Monitor/Modify Tx

lemborexant + cyclobenzaprine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• cyclophosphamide
Dayvigo (lemborexant)

+

cyclophosphamide

1 interaction

Monitor/Modify Tx

lemborexant + cyclophosphamide

monitor CBC, renal, cardiac fxn: combo may incr. cyclophosphamide active metabolite levels, risk of serious infection, myelosuppression, nephrotoxicity, cardiotoxicity, other adverse effects (hepatic metabolism possibly induced, incr. active metabolite formation)

• cyproheptadine
Dayvigo (lemborexant)

+

cyproheptadine

2 interactions

Monitor/Modify Tx

lemborexant + cyproheptadine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dantrolene
Dayvigo (lemborexant)

+

dantrolene

1 interaction

Monitor/Modify Tx

lemborexant + dantrolene

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• darifenacin
Dayvigo (lemborexant)

+

darifenacin

2 interactions

Monitor/Modify Tx

lemborexant + darifenacin

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• desflurane
Dayvigo (lemborexant)

+

desflurane

1 interaction

Monitor/Modify Tx

lemborexant + desflurane

consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• desipramine
Dayvigo (lemborexant)

+

desipramine

1 interaction

Monitor/Modify Tx

lemborexant + desipramine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• desvenlafaxine
Dayvigo (lemborexant)

+

desvenlafaxine

3 interactions

Monitor/Modify Tx

lemborexant + desvenlafaxine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• deutetrabenazine
Dayvigo (lemborexant)

+

deutetrabenazine

1 interaction

Monitor/Modify Tx

lemborexant + deutetrabenazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dexbrompheniramine
Dayvigo (lemborexant)

+

dexbrompheniramine

3 interactions

Monitor/Modify Tx

lemborexant + dexbrompheniramine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dexchlorpheniramine
Dayvigo (lemborexant)

+

dexchlorpheniramine

1 interaction

Monitor/Modify Tx

lemborexant + dexchlorpheniramine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dexmedetomidine
Dayvigo (lemborexant)

+

dexmedetomidine

2 interactions

Monitor/Modify Tx

lemborexant + dexmedetomidine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dexmedetomidine injection
Dayvigo (lemborexant)

+

dexmedetomidine injection

1 interaction

Monitor/Modify Tx

lemborexant + dexmedetomidine injection

monitor respiratory rate, consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• diazepam
Dayvigo (lemborexant)

+

diazepam

2 interactions

Monitor/Modify Tx

lemborexant + diazepam

monitor respiratory rate; consider decr. dose of one or both drugs; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• dichlorphenamide
Dayvigo (lemborexant)

+

dichlorphenamide

1 interaction

Monitor/Modify Tx

lemborexant + dichlorphenamide

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• difelikefalin
Dayvigo (lemborexant)

+

difelikefalin

2 interactions

Monitor/Modify Tx

lemborexant + difelikefalin

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• difenoxin
Dayvigo (lemborexant)

+

difenoxin

1 interaction

Monitor/Modify Tx

lemborexant + difenoxin

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dihydrocodeine
Dayvigo (lemborexant)

+

dihydrocodeine

1 interaction

Monitor/Modify Tx

lemborexant + dihydrocodeine

monitor respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• dimenhydrinate
Dayvigo (lemborexant)

+

dimenhydrinate

1 interaction

Monitor/Modify Tx

lemborexant + dimenhydrinate

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• diosmin
Dayvigo (lemborexant)

+

diosmin

1 interaction

Monitor/Modify Tx

lemborexant + diosmin

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• diphenhydramine
Dayvigo (lemborexant)

+

diphenhydramine

3 interactions

Monitor/Modify Tx

lemborexant + diphenhydramine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• diphenoxylate
Dayvigo (lemborexant)

+

diphenoxylate

1 interaction

Monitor/Modify Tx

lemborexant + diphenoxylate

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• domperidone
Dayvigo (lemborexant)

+

domperidone

2 interactions

Monitor/Modify Tx

lemborexant + domperidone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• doxepin
Dayvigo (lemborexant)

+

doxepin

1 interaction

Monitor/Modify Tx

lemborexant + doxepin

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• doxepin topical
Dayvigo (lemborexant)

+

doxepin topical

2 interactions

Monitor/Modify Tx

lemborexant + doxepin topical

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dronabinol
Dayvigo (lemborexant)

+

dronabinol

1 interaction

Monitor/Modify Tx

lemborexant + dronabinol

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• droperidol
Dayvigo (lemborexant)

+

droperidol

2 interactions

Monitor/Modify Tx

lemborexant + droperidol

decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• eletriptan
Dayvigo (lemborexant)

+

eletriptan

1 interaction

Monitor/Modify Tx

lemborexant + eletriptan

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• elinzanetant
Dayvigo (lemborexant)

+

elinzanetant

2 interactions

Monitor/Modify Tx

lemborexant + elinzanetant

adjust max lemborexant dose to 5 mg/day; consider decr. elinzanetant dose: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• entacapone
Dayvigo (lemborexant)

+

entacapone

1 interaction

Monitor/Modify Tx

lemborexant + entacapone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• entrectinib
Dayvigo (lemborexant)

+

entrectinib

2 interactions

Monitor/Modify Tx

lemborexant + entrectinib

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited; additive effects)

• escitalopram
Dayvigo (lemborexant)

+

escitalopram

1 interaction

Monitor/Modify Tx

lemborexant + escitalopram

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• esketamine
Dayvigo (lemborexant)

+

esketamine

2 interactions

Monitor/Modify Tx

lemborexant + esketamine

monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• eslicarbazepine acetate
Dayvigo (lemborexant)

+

eslicarbazepine acetate

1 interaction

Monitor/Modify Tx

lemborexant + eslicarbazepine acetate

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ethinyl estradiol (contraceptive)
Dayvigo (lemborexant)

+

ethinyl estradiol (contraceptive)

2 interactions

Monitor/Modify Tx

lemborexant + ethinyl estradiol (contraceptive)

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• ethosuximide
Dayvigo (lemborexant)

+

ethosuximide

1 interaction

Monitor/Modify Tx

lemborexant + ethosuximide

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• etomidate
Dayvigo (lemborexant)

+

etomidate

2 interactions

Monitor/Modify Tx

lemborexant + etomidate

monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• everolimus
Dayvigo (lemborexant)

+

everolimus

1 interaction

Monitor/Modify Tx

lemborexant + everolimus

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• felbamate
Dayvigo (lemborexant)

+

felbamate

2 interactions

Monitor/Modify Tx

lemborexant + felbamate

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• fenfluramine
Dayvigo (lemborexant)

+

fenfluramine

1 interaction

Monitor/Modify Tx

lemborexant + fenfluramine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• fentanyl
Dayvigo (lemborexant)

+

fentanyl

2 interactions

Monitor/Modify Tx

lemborexant + fentanyl

monitor respiratory rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• fesoterodine
Dayvigo (lemborexant)

+

fesoterodine

1 interaction

Monitor/Modify Tx

lemborexant + fesoterodine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• finerenone
Dayvigo (lemborexant)

+

finerenone

2 interactions

Monitor/Modify Tx

lemborexant + finerenone

adjust max lemborexant dose to 5 mg/day if on finerenone 40 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• flibanserin
Dayvigo (lemborexant)

+

flibanserin

1 interaction

Monitor/Modify Tx

lemborexant + flibanserin

adjust max lemborexant dose to 5 mg/day; consider decr. flibanserin dose: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• fluoxetine
Dayvigo (lemborexant)

+

fluoxetine

1 interaction

Monitor/Modify Tx

lemborexant + fluoxetine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• fluphenazine
Dayvigo (lemborexant)

+

fluphenazine

1 interaction

Monitor/Modify Tx

lemborexant + fluphenazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• fluvoxamine
Dayvigo (lemborexant)

+

fluvoxamine

1 interaction

Monitor/Modify Tx

lemborexant + fluvoxamine

monitor respiratory rate; adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• fosaprepitant
Dayvigo (lemborexant)

+

fosaprepitant

3 interactions

Monitor/Modify Tx

lemborexant + fosaprepitant

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• foslevodopa
Dayvigo (lemborexant)

+

foslevodopa

1 interaction

Monitor/Modify Tx

lemborexant + foslevodopa

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• fostamatinib
Dayvigo (lemborexant)

+

fostamatinib

2 interactions

Monitor/Modify Tx

lemborexant + fostamatinib

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• frovatriptan
Dayvigo (lemborexant)

+

frovatriptan

1 interaction

Monitor/Modify Tx

lemborexant + frovatriptan

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• gabapentin
Dayvigo (lemborexant)

+

gabapentin

1 interaction

Monitor/Modify Tx

lemborexant + gabapentin

monitor respiratory rate; consider decreasing dose of one or both drugs: combo may increase risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• gabapentin enacarbil
Dayvigo (lemborexant)

+

gabapentin enacarbil

1 interaction

Monitor/Modify Tx

lemborexant + gabapentin enacarbil

monitor respiratory rate, consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• ganaxolone
Dayvigo (lemborexant)

+

ganaxolone

1 interaction

Monitor/Modify Tx

lemborexant + ganaxolone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• gepotidacin
Dayvigo (lemborexant)

+

gepotidacin

3 interactions

Monitor/Modify Tx

lemborexant + gepotidacin

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• ginkgo
Dayvigo (lemborexant)

+

ginkgo

1 interaction

Monitor/Modify Tx

lemborexant + ginkgo

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• givinostat
Dayvigo (lemborexant)

+

givinostat

2 interactions

Monitor/Modify Tx

lemborexant + givinostat

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (GI metabolism inhibited)

• givosiran
Dayvigo (lemborexant)

+

givosiran

1 interaction

Monitor/Modify Tx

lemborexant + givosiran

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• glecaprevir
Dayvigo (lemborexant)

+

glecaprevir

1 interaction

Monitor/Modify Tx

lemborexant + glecaprevir

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• glofitamab
Dayvigo (lemborexant)

+

glofitamab

3 interactions

Monitor/Modify Tx

lemborexant + glofitamab

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• glycopyrrolate
Dayvigo (lemborexant)

+

glycopyrrolate

1 interaction

Monitor/Modify Tx

lemborexant + glycopyrrolate

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• goldenseal
Dayvigo (lemborexant)

+

goldenseal

2 interactions

Monitor/Modify Tx

lemborexant + goldenseal

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• grazoprevir
Dayvigo (lemborexant)

+

grazoprevir

1 interaction

Monitor/Modify Tx

lemborexant + grazoprevir

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• guanfacine
Dayvigo (lemborexant)

+

guanfacine

1 interaction

Monitor/Modify Tx

lemborexant + guanfacine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• hydromorphone
Dayvigo (lemborexant)

+

hydromorphone

1 interaction

Monitor/Modify Tx

lemborexant + hydromorphone

monitor respiratory rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• hydroxyzine
Dayvigo (lemborexant)

+

hydroxyzine

1 interaction

Monitor/Modify Tx

lemborexant + hydroxyzine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• hyoscyamine
Dayvigo (lemborexant)

+

hyoscyamine

1 interaction

Monitor/Modify Tx

lemborexant + hyoscyamine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ifosfamide
Dayvigo (lemborexant)

+

ifosfamide

2 interactions

Monitor/Modify Tx

lemborexant + ifosfamide

monitor CBC, renal, cardiac fxn; consider ifosfamide dose adjustment; consider decr. lemborexant dose; D/C one or both drugs if encephalopathy occurs: combo may incr. ifosfamide active and toxic metabolite levels, risk of myelosuppression, serious infection, encephalopathy, nephrotoxicity, cardiotoxicity, other adverse effects; may incr. risk of CNS depression, psychomotor impairment (hepatic metabolism induced, incr. metabolite formation; additive effects)

• iloperidone
Dayvigo (lemborexant)

+

iloperidone

1 interaction

Monitor/Modify Tx

lemborexant + iloperidone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• imipramine
Dayvigo (lemborexant)

+

imipramine

1 interaction

Monitor/Modify Tx

lemborexant + imipramine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• isoflurane
Dayvigo (lemborexant)

+

isoflurane

3 interactions

Monitor/Modify Tx

lemborexant + isoflurane

consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• isoniazid
Dayvigo (lemborexant)

+

isoniazid

1 interaction

Monitor/Modify Tx

lemborexant + isoniazid

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• istradefylline
Dayvigo (lemborexant)

+

istradefylline

3 interactions

Monitor/Modify Tx

lemborexant + istradefylline

adjust max lemborexant dose to 5 mg/day, especially w/ istradefylline 40 mg dose: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• ivacaftor
Dayvigo (lemborexant)

+

ivacaftor

1 interaction

Monitor/Modify Tx

lemborexant + ivacaftor

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• ketamine
Dayvigo (lemborexant)

+

ketamine

2 interactions

Monitor/Modify Tx

lemborexant + ketamine

monitor respiratory rate; consider decr. dose of one or both drugs; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression (including life-threatening), psychomotor impairment (additive effects)

• lacosamide
Dayvigo (lemborexant)

+

lacosamide

1 interaction

Monitor/Modify Tx

lemborexant + lacosamide

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• lamotrigine
Dayvigo (lemborexant)

+

lamotrigine

2 interactions

Monitor/Modify Tx

lemborexant + lamotrigine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• lapatinib
Dayvigo (lemborexant)

+

lapatinib

1 interaction

Monitor/Modify Tx

lemborexant + lapatinib

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• larotrectinib
Dayvigo (lemborexant)

+

larotrectinib

2 interactions

Monitor/Modify Tx

lemborexant + larotrectinib

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• lazertinib
Dayvigo (lemborexant)

+

lazertinib

1 interaction

Monitor/Modify Tx

lemborexant + lazertinib

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• levetiracetam
Dayvigo (lemborexant)

+

levetiracetam

1 interaction

Monitor/Modify Tx

lemborexant + levetiracetam

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• levocetirizine
Dayvigo (lemborexant)

+

levocetirizine

3 interactions

Monitor/Modify Tx

lemborexant + levocetirizine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• levodopa
Dayvigo (lemborexant)

+

levodopa

1 interaction

Monitor/Modify Tx

lemborexant + levodopa

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• levomilnacipran
Dayvigo (lemborexant)

+

levomilnacipran

2 interactions

Monitor/Modify Tx

lemborexant + levomilnacipran

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• levorphanol
Dayvigo (lemborexant)

+

levorphanol

1 interaction

Monitor/Modify Tx

lemborexant + levorphanol

monitor respiratory rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• linvoseltamab
Dayvigo (lemborexant)

+

linvoseltamab

2 interactions

Monitor/Modify Tx

lemborexant + linvoseltamab

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• lofexidine
Dayvigo (lemborexant)

+

lofexidine

1 interaction

Monitor/Modify Tx

lemborexant + lofexidine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• lomitapide
Dayvigo (lemborexant)

+

lomitapide

2 interactions

Monitor/Modify Tx

lemborexant + lomitapide

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• lorazepam
Dayvigo (lemborexant)

+

lorazepam

1 interaction

Monitor/Modify Tx

lemborexant + lorazepam

monitor respiratory rate, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• lovastatin
Dayvigo (lemborexant)

+

lovastatin

2 interactions

Monitor/Modify Tx

lemborexant + lovastatin

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• lumateperone
Dayvigo (lemborexant)

+

lumateperone

1 interaction

Monitor/Modify Tx

lemborexant + lumateperone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• lurasidone
Dayvigo (lemborexant)

+

lurasidone

3 interactions

Monitor/Modify Tx

lemborexant + lurasidone

consider decr. dose of one or both drugs; adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• maribavir
Dayvigo (lemborexant)

+

maribavir

1 interaction

Monitor/Modify Tx

lemborexant + maribavir

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• mavorixafor
Dayvigo (lemborexant)

+

mavorixafor

2 interactions

Monitor/Modify Tx

lemborexant + mavorixafor

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• meclizine
Dayvigo (lemborexant)

+

meclizine

1 interaction

Monitor/Modify Tx

lemborexant + meclizine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• melatonin
Dayvigo (lemborexant)

+

melatonin

1 interaction

Monitor/Modify Tx

lemborexant + melatonin

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• meperidine
Dayvigo (lemborexant)

+

meperidine

1 interaction

Monitor/Modify Tx

lemborexant + meperidine

monitor respiratory rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may decr. meperidine levels, efficacy; may incr. normeperidine levels, risk of neurotoxicity; may incr. risk of profound CNS and respiratory depression, psychomotor impairment (hepatic metabolism induced, incr. toxic metabolite formation; additive effects)

• meprobamate
Dayvigo (lemborexant)

+

meprobamate

1 interaction

Monitor/Modify Tx

lemborexant + meprobamate

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• methadone
Dayvigo (lemborexant)

+

methadone

3 interactions

Monitor/Modify Tx

lemborexant + methadone

monitor respiratory rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may decr. methadone levels, efficacy; may incr. risk of profound CNS and respiratory depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• methocarbamol
Dayvigo (lemborexant)

+

methocarbamol

1 interaction

Monitor/Modify Tx

lemborexant + methocarbamol

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• methohexital
Dayvigo (lemborexant)

+

methohexital

2 interactions

Monitor/Modify Tx

lemborexant + methohexital

consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• methsuximide
Dayvigo (lemborexant)

+

methsuximide

1 interaction

Monitor/Modify Tx

lemborexant + methsuximide

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• methyldopa
Dayvigo (lemborexant)

+

methyldopa

2 interactions

Monitor/Modify Tx

lemborexant + methyldopa

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• metyrapone
Dayvigo (lemborexant)

+

metyrapone

1 interaction

Monitor/Modify Tx

lemborexant + metyrapone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• metyrosine
Dayvigo (lemborexant)

+

metyrosine

1 interaction

Monitor/Modify Tx

lemborexant + metyrosine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• milnacipran
Dayvigo (lemborexant)

+

milnacipran

3 interactions

Monitor/Modify Tx

lemborexant + milnacipran

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• milsaperidone
Dayvigo (lemborexant)

+

milsaperidone

1 interaction

Monitor/Modify Tx

lemborexant + milsaperidone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• mirtazapine
Dayvigo (lemborexant)

+

mirtazapine

2 interactions

Monitor/Modify Tx

lemborexant + mirtazapine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• molindone
Dayvigo (lemborexant)

+

molindone

1 interaction

Monitor/Modify Tx

lemborexant + molindone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• morphine
Dayvigo (lemborexant)

+

morphine

2 interactions

Monitor/Modify Tx

lemborexant + morphine

monitor respiratory rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• mosunetuzumab
Dayvigo (lemborexant)

+

mosunetuzumab

1 interaction

Monitor/Modify Tx

lemborexant + mosunetuzumab

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• mycophenolate mofetil
Dayvigo (lemborexant)

+

mycophenolate mofetil

2 interactions

Monitor/Modify Tx

lemborexant + mycophenolate mofetil

consider decr. lemborexant dose: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• nalbuphine
Dayvigo (lemborexant)

+

nalbuphine

1 interaction

Monitor/Modify Tx

lemborexant + nalbuphine

monitor respiratory rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• naltrexone
Dayvigo (lemborexant)

+

naltrexone

1 interaction

Monitor/Modify Tx

lemborexant + naltrexone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• nelarabine
Dayvigo (lemborexant)

+

nelarabine

1 interaction

Monitor/Modify Tx

lemborexant + nelarabine

consider decr. dose of one or both drugs; withhold nelarabine if Grade 2 or greater somnolence occurs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• nicardipine
Dayvigo (lemborexant)

+

nicardipine

1 interaction

Monitor/Modify Tx

lemborexant + nicardipine

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• nortriptyline
Dayvigo (lemborexant)

+

nortriptyline

1 interaction

Monitor/Modify Tx

lemborexant + nortriptyline

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• olanzapine
Dayvigo (lemborexant)

+

olanzapine

3 interactions

Monitor/Modify Tx

lemborexant + olanzapine

monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis (additive effects)

• oliceridine
Dayvigo (lemborexant)

+

oliceridine

1 interaction

Monitor/Modify Tx

lemborexant + oliceridine

monitor respiratory rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, hypotension (additive effects)

• opicapone
Dayvigo (lemborexant)

+

opicapone

2 interactions

Monitor/Modify Tx

lemborexant + opicapone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• opium
Dayvigo (lemborexant)

+

opium

1 interaction

Monitor/Modify Tx

lemborexant + opium

monitor respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• orphenadrine
Dayvigo (lemborexant)

+

orphenadrine

1 interaction

Monitor/Modify Tx

lemborexant + orphenadrine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• osilodrostat
Dayvigo (lemborexant)

+

osilodrostat

1 interaction

Monitor/Modify Tx

lemborexant + osilodrostat

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• oxazepam
Dayvigo (lemborexant)

+

oxazepam

2 interactions

Monitor/Modify Tx

lemborexant + oxazepam

monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• oxcarbazepine
Dayvigo (lemborexant)

+

oxcarbazepine

1 interaction

Monitor/Modify Tx

lemborexant + oxcarbazepine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• oxybutynin
Dayvigo (lemborexant)

+

oxybutynin

1 interaction

Monitor/Modify Tx

lemborexant + oxybutynin

decr. dose of one or both drugs or consider oxybutynin transdermal patch: combo may incr. risk of CNS depression, psychomotor impairment; somnolence less likely with oxybutynin transdermal patch (additive effects)

• oxycodone
Dayvigo (lemborexant)

+

oxycodone

3 interactions

Monitor/Modify Tx

lemborexant + oxycodone

monitor respiratory rate; decr. oxycodone start dose by at least 50%, consider decr. lemborexant dose, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• oxymorphone
Dayvigo (lemborexant)

+

oxymorphone

1 interaction

Monitor/Modify Tx

lemborexant + oxymorphone

monitor respiratory rate; decr. oxymorphone start dose by at least 50%, consider decr. lemborexant dose, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• palbociclib
Dayvigo (lemborexant)

+

palbociclib

2 interactions

Monitor/Modify Tx

lemborexant + palbociclib

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• paliperidone
Dayvigo (lemborexant)

+

paliperidone

1 interaction

Monitor/Modify Tx

lemborexant + paliperidone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• paroxetine
Dayvigo (lemborexant)

+

paroxetine

2 interactions

Monitor/Modify Tx

lemborexant + paroxetine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• pazopanib
Dayvigo (lemborexant)

+

pazopanib

1 interaction

Monitor/Modify Tx

lemborexant + pazopanib

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• pentazocine
Dayvigo (lemborexant)

+

pentazocine

1 interaction

Monitor/Modify Tx

lemborexant + pentazocine

monitor respiratory rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• peppermint
Dayvigo (lemborexant)

+

peppermint

1 interaction

Monitor/Modify Tx

lemborexant + peppermint

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• perampanel
Dayvigo (lemborexant)

+

perampanel

1 interaction

Monitor/Modify Tx

lemborexant + perampanel

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• perphenazine
Dayvigo (lemborexant)

+

perphenazine

3 interactions

Monitor/Modify Tx

lemborexant + perphenazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• pheniramine
Dayvigo (lemborexant)

+

pheniramine

1 interaction

Monitor/Modify Tx

lemborexant + pheniramine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• pibrentasvir
Dayvigo (lemborexant)

+

pibrentasvir

3 interactions

Monitor/Modify Tx

lemborexant + pibrentasvir

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• pimozide
Dayvigo (lemborexant)

+

pimozide

1 interaction

Monitor/Modify Tx

lemborexant + pimozide

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• pirtobrutinib
Dayvigo (lemborexant)

+

pirtobrutinib

2 interactions

Monitor/Modify Tx

lemborexant + pirtobrutinib

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• pramipexole
Dayvigo (lemborexant)

+

pramipexole

1 interaction

Monitor/Modify Tx

lemborexant + pramipexole

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• pregabalin
Dayvigo (lemborexant)

+

pregabalin

2 interactions

Monitor/Modify Tx

lemborexant + pregabalin

monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• primaquine
Dayvigo (lemborexant)

+

primaquine

1 interaction

Monitor/Modify Tx

lemborexant + primaquine

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism possibly inhibited)

• procarbazine
Dayvigo (lemborexant)

+

procarbazine

1 interaction

Monitor/Modify Tx

lemborexant + procarbazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• prochlorperazine
Dayvigo (lemborexant)

+

prochlorperazine

3 interactions

Monitor/Modify Tx

lemborexant + prochlorperazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• propofol
Dayvigo (lemborexant)

+

propofol

1 interaction

Monitor/Modify Tx

lemborexant + propofol

monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• protriptyline
Dayvigo (lemborexant)

+

protriptyline

2 interactions

Monitor/Modify Tx

lemborexant + protriptyline

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• pyrilamine
Dayvigo (lemborexant)

+

pyrilamine

1 interaction

Monitor/Modify Tx

lemborexant + pyrilamine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• quercetin
Dayvigo (lemborexant)

+

quercetin

2 interactions

Monitor/Modify Tx

lemborexant + quercetin

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• quetiapine
Dayvigo (lemborexant)

+

quetiapine

1 interaction

Monitor/Modify Tx

lemborexant + quetiapine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ranolazine
Dayvigo (lemborexant)

+

ranolazine

1 interaction

Monitor/Modify Tx

lemborexant + ranolazine

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• rasagiline
Dayvigo (lemborexant)

+

rasagiline

3 interactions

Monitor/Modify Tx

lemborexant + rasagiline

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• remdesivir
Dayvigo (lemborexant)

+

remdesivir

1 interaction

Monitor/Modify Tx

lemborexant + remdesivir

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• remimazolam
Dayvigo (lemborexant)

+

remimazolam

1 interaction

Monitor/Modify Tx

lemborexant + remimazolam

monitor respiratory rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• resveratrol
Dayvigo (lemborexant)

+

resveratrol

3 interactions

Monitor/Modify Tx

lemborexant + resveratrol

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• risperidone
Dayvigo (lemborexant)

+

risperidone

1 interaction

Monitor/Modify Tx

lemborexant + risperidone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ritlecitinib
Dayvigo (lemborexant)

+

ritlecitinib

3 interactions

Monitor/Modify Tx

lemborexant + ritlecitinib

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• rizatriptan
Dayvigo (lemborexant)

+

rizatriptan

1 interaction

Monitor/Modify Tx

lemborexant + rizatriptan

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ropinirole
Dayvigo (lemborexant)

+

ropinirole

2 interactions

Monitor/Modify Tx

lemborexant + ropinirole

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• rotigotine transdermal
Dayvigo (lemborexant)

+

rotigotine transdermal

1 interaction

Monitor/Modify Tx

lemborexant + rotigotine transdermal

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• rucaparib
Dayvigo (lemborexant)

+

rucaparib

2 interactions

Monitor/Modify Tx

lemborexant + rucaparib

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• rufinamide
Dayvigo (lemborexant)

+

rufinamide

1 interaction

Monitor/Modify Tx

lemborexant + rufinamide

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• safinamide
Dayvigo (lemborexant)

+

safinamide

2 interactions

Monitor/Modify Tx

lemborexant + safinamide

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• selegiline
Dayvigo (lemborexant)

+

selegiline

1 interaction

Monitor/Modify Tx

lemborexant + selegiline

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• selegiline transdermal
Dayvigo (lemborexant)

+

selegiline transdermal

1 interaction

Monitor/Modify Tx

lemborexant + selegiline transdermal

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• selinexor
Dayvigo (lemborexant)

+

selinexor

3 interactions

Monitor/Modify Tx

lemborexant + selinexor

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• selpercatinib
Dayvigo (lemborexant)

+

selpercatinib

1 interaction

Monitor/Modify Tx

lemborexant + selpercatinib

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• sertraline
Dayvigo (lemborexant)

+

sertraline

2 interactions

Monitor/Modify Tx

lemborexant + sertraline

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• sevoflurane
Dayvigo (lemborexant)

+

sevoflurane

1 interaction

Monitor/Modify Tx

lemborexant + sevoflurane

monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• solifenacin
Dayvigo (lemborexant)

+

solifenacin

2 interactions

Monitor/Modify Tx

lemborexant + solifenacin

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• spironolactone
Dayvigo (lemborexant)

+

spironolactone

1 interaction

Monitor/Modify Tx

lemborexant + spironolactone

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism possibly inhibited)

• stiripentol
Dayvigo (lemborexant)

+

stiripentol

2 interactions

Monitor/Modify Tx

lemborexant + stiripentol

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited; additive effects)

• sufentanil
Dayvigo (lemborexant)

+

sufentanil

1 interaction

Monitor/Modify Tx

lemborexant + sufentanil

monitor respiratory rate, decr. sufentanil start dose, consider decr. lemborexant dose, use lowest effective doses: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• sumatriptan
Dayvigo (lemborexant)

+

sumatriptan

1 interaction

Monitor/Modify Tx

lemborexant + sumatriptan

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tapentadol
Dayvigo (lemborexant)

+

tapentadol

1 interaction

Monitor/Modify Tx

lemborexant + tapentadol

monitor respiratory rate, BP; decrease dose of one or both drugs, use lowest effective doses and shortest duration of concomitant treatment: combo may increase risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• tasimelteon
Dayvigo (lemborexant)

+

tasimelteon

1 interaction

Monitor/Modify Tx

lemborexant + tasimelteon

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tetrabenazine
Dayvigo (lemborexant)

+

tetrabenazine

3 interactions

Monitor/Modify Tx

lemborexant + tetrabenazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• thioridazine
Dayvigo (lemborexant)

+

thioridazine

1 interaction

Monitor/Modify Tx

lemborexant + thioridazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• thiotepa
Dayvigo (lemborexant)

+

thiotepa

2 interactions

Monitor/Modify Tx

lemborexant + thiotepa

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• thiothixene
Dayvigo (lemborexant)

+

thiothixene

1 interaction

Monitor/Modify Tx

lemborexant + thiothixene

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tiagabine
Dayvigo (lemborexant)

+

tiagabine

2 interactions

Monitor/Modify Tx

lemborexant + tiagabine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ticagrelor
Dayvigo (lemborexant)

+

ticagrelor

1 interaction

Monitor/Modify Tx

lemborexant + ticagrelor

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• tizanidine
Dayvigo (lemborexant)

+

tizanidine

2 interactions

Monitor/Modify Tx

lemborexant + tizanidine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tolcapone
Dayvigo (lemborexant)

+

tolcapone

1 interaction

Monitor/Modify Tx

lemborexant + tolcapone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tolterodine
Dayvigo (lemborexant)

+

tolterodine

1 interaction

Monitor/Modify Tx

lemborexant + tolterodine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tolvaptan
Dayvigo (lemborexant)

+

tolvaptan

3 interactions

Monitor/Modify Tx

lemborexant + tolvaptan

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• topiramate
Dayvigo (lemborexant)

+

topiramate

1 interaction

Monitor/Modify Tx

lemborexant + topiramate

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tramadol
Dayvigo (lemborexant)

+

tramadol

2 interactions

Monitor/Modify Tx

lemborexant + tramadol

monitor respiratory rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• trazodone
Dayvigo (lemborexant)

+

trazodone

1 interaction

Monitor/Modify Tx

lemborexant + trazodone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• treosulfan
Dayvigo (lemborexant)

+

treosulfan

2 interactions

Monitor/Modify Tx

lemborexant + treosulfan

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism possibly inhibited)

• trifluoperazine
Dayvigo (lemborexant)

+

trifluoperazine

1 interaction

Monitor/Modify Tx

lemborexant + trifluoperazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• trihexyphenidyl
Dayvigo (lemborexant)

+

trihexyphenidyl

2 interactions

Monitor/Modify Tx

lemborexant + trihexyphenidyl

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• trimipramine
Dayvigo (lemborexant)

+

trimipramine

1 interaction

Monitor/Modify Tx

lemborexant + trimipramine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• triprolidine
Dayvigo (lemborexant)

+

triprolidine

1 interaction

Monitor/Modify Tx

lemborexant + triprolidine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• trofinetide
Dayvigo (lemborexant)

+

trofinetide

3 interactions

Monitor/Modify Tx

lemborexant + trofinetide

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (GI metabolism inhibited)

• trospium
Dayvigo (lemborexant)

+

trospium

1 interaction

Monitor/Modify Tx

lemborexant + trospium

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• valbenazine
Dayvigo (lemborexant)

+

valbenazine

2 interactions

Monitor/Modify Tx

lemborexant + valbenazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• valerian
Dayvigo (lemborexant)

+

valerian

1 interaction

Monitor/Modify Tx

lemborexant + valerian

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• valproic acid
Dayvigo (lemborexant)

+

valproic acid

2 interactions

Monitor/Modify Tx

lemborexant + valproic acid

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• venlafaxine
Dayvigo (lemborexant)

+

venlafaxine

1 interaction

Monitor/Modify Tx

lemborexant + venlafaxine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• vigabatrin
Dayvigo (lemborexant)

+

vigabatrin

2 interactions

Monitor/Modify Tx

lemborexant + vigabatrin

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• vilazodone
Dayvigo (lemborexant)

+

vilazodone

1 interaction

Monitor/Modify Tx

lemborexant + vilazodone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• viloxazine
Dayvigo (lemborexant)

+

viloxazine

1 interaction

Monitor/Modify Tx

lemborexant + viloxazine

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• vonoprazan
Dayvigo (lemborexant)

+

vonoprazan

3 interactions

Monitor/Modify Tx

lemborexant + vonoprazan

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• xanomeline
Dayvigo (lemborexant)

+

xanomeline

1 interaction

Monitor/Modify Tx

lemborexant + xanomeline

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (GI metabolism possibly inhibited)

• ziconotide
Dayvigo (lemborexant)

+

ziconotide

2 interactions

Monitor/Modify Tx

lemborexant + ziconotide

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ziftomenib
Dayvigo (lemborexant)

+

ziftomenib

1 interaction

Monitor/Modify Tx

lemborexant + ziftomenib

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• zileuton
Dayvigo (lemborexant)

+

zileuton

2 interactions

Monitor/Modify Tx

lemborexant + zileuton

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• ziprasidone
Dayvigo (lemborexant)

+

ziprasidone

2 interactions

Monitor/Modify Tx

lemborexant + ziprasidone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• zolmitriptan
Dayvigo (lemborexant)

+

zolmitriptan

1 interaction

Monitor/Modify Tx

lemborexant + zolmitriptan

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• zonisamide
Dayvigo (lemborexant)

+

zonisamide

2 interactions

Monitor/Modify Tx

lemborexant + zonisamide

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

Caution Advised

• brimonidine ophthalmic
Dayvigo (lemborexant)

+

brimonidine ophthalmic

1 interaction

Caution Advised

lemborexant + brimonidine ophthalmic

caution advised if elevated IOP or presbyopia use; OTC ocular redness use OK: combo may increase risk of CNS depression, psychomotor impairment (additive effects)

• bupropion
Dayvigo (lemborexant)

+

bupropion

2 interactions

Caution Advised

lemborexant + bupropion

caution advised: combo may decr. bupropion and metabolite levels, efficacy (hepatic metabolism induced)

• nevirapine
Dayvigo (lemborexant)

+

nevirapine

1 interaction

Caution Advised

lemborexant + nevirapine

caution advised: combo may decr. nevirapine levels, efficacy (hepatic metabolism induced)

• passion flower
Dayvigo (lemborexant)

+

passion flower

2 interactions

Caution Advised

lemborexant + passion flower

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• velpatasvir
Dayvigo (lemborexant)

+

velpatasvir

1 interaction

Caution Advised

lemborexant + velpatasvir

caution advised: combo may decr. velpatasvir levels, efficacy (hepatic metabolism induced)